MYRIAD GENETICS DL-,01 | 18,695 / 0,00% |
日付/時刻 | 07.07. / 11:43 |
変化 / 変化(%) | 0,000 / 0,00% |
Bid | 18,615 / 140 |
Ask | 18,780 / 140 |
始値 | 18,695 |
直前終値 | 18,695 |
高値 | 18,695 |
安値 | 18,695 |
出来高 [EUR] | - |
出来高 [Units] | |
Price fixings | 4 |
ISIN | US62855J1043 |
シンボル | MYD |
取引所 | gettex |
種類 | 株式 |
すべての取引所
取引所 | 直近 | 出来高 | |
---|---|---|---|
Hannover | 18,590 | ![]() |
0 |
Frankfurt | 18,5800 | ![]() |
0 |
Berlin | 18,595 | ![]() |
0 |
München | 18,570 | ![]() |
0 |
Hamburg | 18,590 | ![]() |
0 |
Düsseldorf | 18,645 | ![]() |
0 |
Lang & Schwa.. | 18,635 | ![]() |
|
Stuttgart | 18,580 | ![]() |
|
gettex | 18,695 | ![]() |
|
Quotrix | 18,6600 | ![]() |
|
NASDAQ | 19,0100 | ![]() |
390.184 |
IEX | 19,01 | ![]() |
26.089 |
Cboe US | 18,99 | 16.515 | |
Xetra | 17,840 | 0 | |
London Domes.. | 19,45 | 31 | |
TradeGate | 16,450 | 600 |
ニュース
- Myriad Genetics Advances Precision Oncology with New Precise™ Solutions, Combines Genetic Insights from Multiple Tests to Guide Treatment Decisions and Improve Patient Care
14.03.2022 / 12:05 - GlobeNewswire - Myriad Genetics Receives FDA Approval of BRACAnalysis® CDx as a Companion Diagnostic for Lynparza® in Early Breast Cancer
12.03.2022 / 01:05 - GlobeNewswire - Myriad Genetics Named to Fast Company’s Annual List of World’s Most Innovative Companies
08.03.2022 / 13:22 - GlobeNewswire - Myriad Genetics CEO Paul Diaz to Speak at 42nd Annual Cowen Health Care Conference
02.03.2022 / 22:30 - GlobeNewswire - Myriad Genetics Reports Fourth Quarter 2021 Results, Provides Updates on Product Performance and Growth Initiatives
24.02.2022 / 15:00 - GlobeNewswire
Personal area
Click on
to activate push quotes.
